China Proceeds with mRNA RSV Vaccine Candidate

The board of directors of CSPC Pharmaceutical Group Limited announced on July 11, 2024, that the mRNA Respiratory Syncytial Virus (RSV) vaccine candidate (SYS6016) has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct human clinical trials in China.

Currently, there is no vaccine available in China that protects people from RSV infection.

In preclinical studies, SYS6016 translated into the prefusion conformation F-protein in vivo and induced high titers of long-lasting neutralizing antibodies.

CSPC wrote that this vaccine candidate exhibits good protection against RSV-A and RSV-B subtype viral strains and has a good safety profile.

CSPC confirmed it would endeavor to advance the clinical research and market SYS6016 as soon as possible to create value for society and shareholders.

As of July 13, 2024, three RSV vaccines and one monoclonal antibody for infants (Beyfortus) were approved for use in the United States.